$14.630
-1.091 (-7.46%)Al cierre
Comparativa sectorial de BLSM
In the context of the broader market, BLSM competes directly with industry leaders such as PHAT and EOLS. With a market capitalization of $465.01M, it holds a leading position in the sector. When comparing efficiency, BLSM's gross margin of N/A stands against PHAT's 79.68% and EOLS's 66.19%. Such benchmarking helps identify whether BlossomHill Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Desempeño financiero de BlossomHill Therapeutics Inc
The company reported a net income of -$23,758,000 in Q2 2026, reflecting ongoing losses, but it has a strong current ratio of 5.42, indicating good short-term financial health.
Financials
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.